For the generics, especially, yes. It's to a limited extent when it comes to single-source products that are of equal benefit.
Senior Policy Advisor on Pricing and Reimbursement of Pharmaceuticals, Department of Pharmaceutical Affairs and Medical Technology, Dutch Ministry of Health, Welfare and Sports
For the generics, especially, yes. It's to a limited extent when it comes to single-source products that are of equal benefit.
See context to find out what was said next.